Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience.

被引：3
|
作者：
Lau, Sally C. M.
Perdrizet, Kirstin
Mata, Danilo Giffoni de Mello Morais
Fung, Andrea S.
Liu, Geoffrey
Bradbury, Penelope Ann
Shepherd, Frances A.
Sacher, Adrian G.
Sheffield, Brandon
Hwang, David
Tsao, Ming Sound
Cheng, Susanna Y.
Cheema, Parneet
Leighl, Natasha B.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Canc Ctr Southeastern Ontario, Kingston, ON, Canada
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[7] William Osler Hlth Ctr, Brampton, ON, Canada
[8] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[9] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[10] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21123
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations
    Felip, E.
    Sakai, H.
    Patel, J.
    Horn, L.
    Veillon, R.
    Griesinger, F.
    Bruns, R.
    Scheele, J.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S347 - S347
  • [22] Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation
    Wolf, J.
    Heist, R.
    Kim, T. M.
    Nishio, M.
    Dooms, C.
    Kanthala, R. R.
    Leo, E.
    Giorgetti, E.
    Wang, Y.
    Mardjuadi, F. I.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1007 - S1008
  • [23] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Terufumi Kato
    James Chih-Hsin Yang
    Myung-Ju Ahn
    Hiroshi Sakai
    Masahiro Morise
    Yuh-Min Chen
    Ji-Youn Han
    Jin-Ji Yang
    Jun Zhao
    Te-Chun Hsia
    Karin Berghoff
    Rolf Bruns
    Helene Vioix
    Simone Lang
    Andreas Johne
    Xiuning Le
    Paul K. Paik
    British Journal of Cancer, 2024, 130 : 1679 - 1686
  • [24] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Hsia, Te-Chun
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Lang, Simone
    Johne, Andreas
    Le, Xiuning
    Paik, Paul K.
    BRITISH JOURNAL OF CANCER, 2024, 130 (10) : 1679 - 1686
  • [25] MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC
    Di Maio, Massimo
    Bironzo, Paolo
    Scagliotti, Giorgio Vittorio
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S101 - S105
  • [26] Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
    Ignatius, Sai-Hong
    Young, Lauren
    Schrock, Alexa B.
    Johnson, Adrienne
    Klempner, Samuel J.
    Zhu, Viola W.
    Miller, Vincent A.
    Ali, Siraj M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 137 - 140
  • [27] Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
    Lau, Sally C. M.
    Perdrizet, Kirstin
    Fung, Andrea S.
    Mata, Danilo Giffoni M. M.
    Weiss, Jessica
    Holzapfel, Nick
    Liu, Geoffrey
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Sacher, Adrian G.
    Feilotter, Harriet
    Field, Brandon Shef
    Hwang, David
    Sound, Ming
    Cheng, Susanna
    Cheema, Parneet
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
  • [28] Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC
    Yasuda, Hiroyuki
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 679 - 680
  • [29] Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
    Krebs, Matthew
    Spira, Alexander I.
    Cho, Byoung Chul
    Besse, Benjamin
    Goldman, Jonathan W.
    Janne, Pasi A.
    Ma, Zhiyong
    Mansfield, Aaron Scott
    Minchom, Anna Rachel
    Ou, Sai-Hong Ignatius
    Salgia, Ravi
    Wang, Zhijie
    Perez, Casilda Llacer
    Gao, Grace
    Curtin, Joshua C.
    Roshak, Amy
    Schnepp, Robert W.
    Thayu, Meena
    Knoblauch, Roland
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Adenosquamous carcinoma of the lung - biopsy: MET exon 14 skipping mutation
    Sousa, V.
    Alarcao, A.
    Ladeirinha, A.
    Silva, M. Reis
    Ferreira, T.
    Rodrigues, A.
    Vilasboas, C.
    Carvalho, L.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S333 - S333
12345